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ABSTRACT
In a 2004 paper, John Nagy raised the possibility of the existence of a hypertumor i.e., a
focus of aggressively reproducing parenchyma cells that invade part or all of a tumor. His model
used a system of nonlinear ordinary differential equations to find a suitable set of conditions for
which these hypertumors exist. Here that model is expanded by transforming it into a system of
nonlinear partial differential equations with diffusion, advection, and a free boundary condition to
represent a radially symmetric tumor growth. Two strains of parenchymal cells are incorporated;
one forming almost the entirety of the tumor while the much more aggressive strain appears in
a smaller region inside of the tumor. Simulations show that if the aggressive strain focuses its
efforts on proliferating and does not contribute to angiogenesis signaling when in a hypoxic state,
a hypertumor will form. More importantly, this resultant aggressive tumor is paradoxically prone
to extinction and hypothesize is the cause of necrosis in many vascularized tumors.
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Chapter 1
INTRODUCTION
Douglas Hanahan and Robert Weinberg first presented their theory about conditions for tumor
growth in 2000 (and expanded it in 2011). The theory suggests tumorigenesis occurs when (and
only when) a single cell acquires the following six characteristics: (1) self-sustaining proliferative
signaling, (2) evading external sources of growth suppression, (3) resisting apoptotic signals, (4)
promoting tumor angiogenesis, (5) enabling replicative immortality, and (6) ability to invade sur-
rounding tissue and metastasize [26]. While these traits are usually sufficient, they are not necessary
but it demonstrates cancer is an evolutionary process; any mutations that redirect more of the body's
resources to cancer cells will be selected [32].
Malignant tumors arise from previously healthy and genomically intact cells and are made up
of various cell phenotypes, both cancerous (parenchyma) and heathy (stroma). They affect almost
all classes of vertebrates but appear to be most common in mammals [20, 21]. Tumors evolve
by clonal selection of cell populations that proliferate in an unconstrained manner, accumulate
mutations, and compete for nutrients or space [2]. These tumors tend to share similar characteristic
behaviors of, uncontrolled growth, lack of tissue integration, invasion of surrounding tissue, and
metastasis [37]. Natural selection always favors more aggressive parenchyma cell phenotypes [31].
Nagy tried to answer the following two questions in 2004 [36]. First, what allows for
parenchyma diversity and the tissue-like organization among parenchymal and stromal subpop-
ulations? Secondly, how will the parenchyma population evolve over time? He argued if tumors
act like ecological communities, then cell types should segregate into distinct niches and live off
of different sets of resources because of competitive exclusion [36]. However, if tumors are more
like integrated tissues, natural selection should favor diverse but cooperative cell types. His results
showed that if a mutant cell type becomes established within a tumor, and that cell type applies
more resources to proliferation than residents do, then the mutant type will tend to invade, even-
tually become established within and often dominate the tumor [36]. Paradoxically, his model also
showed selection can favor phenotypes that eventually destroy part or perhaps all of the tumor - a
situation he refers to as a hypertumor. The hypertumor mechanism may be a cause of the necrosis
1
observed in many vascularized tumors [36].
The work published since the appearance of Nagy's article has consisted mainly of biolog-
ical/evolutionary reviews on cancer growth (see [15, 25, 23, 31, 33, 13, 4, 34]). The mathematical
models since then have addressed a variety of topics. In Thalhauser et al 's paper [47], the authors
model a tumor cord - growing tumor tissue surrounding pre-existing blood microvessels - but allow
the two phenotypes to carry out one process each, either cell growth or motility. Their results were
that overly aggressive growers would have a greater chance of causing microvessel collapse, ischemia,
and eventual starvation and death to all cells in the local area and, conversely, aggressive movers
would be less likely to cause ischemia. They hypothesize that prevention of ischemia is a selective
force in favor of the aggressively motile cells, even before a tumor becomes metastatic. Their version
of the hypertumor is analogous to the aggressive grower class and they hypothesize that evolution of
the grower class is selected against by the instability it can cause in the local vascular network. The
main differences between our model and Thalhauser et al 's model are that both of our parenchyma
phenotypes are able to carry out both processes, motility and growth, compete for resources, and
also that our domain has a free boundary.
In the work done by Nagy and Armbruster [39], the authors return to the model in [36] and
add energy management via ATP to the model to investigate if ATP can lead to an evolutionary
description of the angiogenic switch. The results in their paper [39] are in line with those of [36]
and additionally show that the strategy leading to extreme vascular hyperplasia may explain the
vascular hyperplasia evident in certain tumor types. This model [39] is described by a system of
ODEs, thus not taking into account any of the spatial effects of the system. Other models address
the question of whether hypertumors can be caused by tumor phosphorous demand [38], which we
do not explore in our model.
There has been plenty of work done using free-boundary value problems to resolve questions
stemming from mathematical oncology (for a review, please see [3, 35, 42]). Tumorigenesis is an
ideal candidate for free-boundary problems because we are interested the way tumors advance in
time and in space, and, since tumors are living tissue, they should be able to move around, grow, and
spread. The mathematical modeling of tumor growth via free-boundary problems can be split into
two categories, those that model avascular tumors and those that model vascular tumors. The bulk
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of the published material falls into the former group (see [16, 8, 6, 18, 42, 43] and references therein)
because they are modeling tumors in vitro. The few vascular tumor models either do not include
necrosis [19] or fail to capture the competition between competing phenotypes [14]. Those that do
contain both competition and necrosis are primarily concerned with the effect of drug treatment to
reduce the overall size of the tumor [28, 27].
In our model, we modify the definition of a hypertumor to incorporate spatial effects as
well. Hypertumors arise, in our model, when a mutant cell type applies more resources locally to
reproduction than the residents do and causes the growth in that region to become negative. If
the density of the resident strain decreases in that region only, or in the whole tumor region in
the case that the resident strain gets wiped out, we call this a hypertumor. Our findings back
Nagy's results indicating that heterogeneous tumors behave more like ecological systems than like
integrated tissues when taking into consideration spatial effects of the system.
Our study seeks to answer three questions about the hypertumor phenomenon through
mathematical modeling and simulation. Can the mechanism account for necrosis in vascularized
tumors? Dr. Nagy [36] hypothesized that it could, and if our spatial model can show the appearance
of necrosis in simulated situations similar to those in which they are observed in vivo, this will help
to support the concept that necrosis can be caused by hyertumors.
Additionally, we would like show that hypertumors can cause tumors to shrink in size. If
hypertumors can cause resource instability along the boundary of the tumor, this would cause the
tumor to reduce in size since the cells in that region would necrose and then wash away via the
advective flow.
Lastly, there are different kinds of tumors in which there is a separation between different
parenchymal cells, e.g. squamous cell carcinoma. If we show that the hypertumor mechanism can
also describe this process of separation, it would illuminate how prominent this mechanism may be
in nature.
We address these questions by formulating a mathematical model that describes three as-
pects of a single solid tumor: change in mass over time and space; change in tumor vascularization
over time and space; and competition between two different parenchyma cell types. Furthermore,
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we assume the tumor occupies a well-defined region in space and the boundary of this region is held
together by the forces of cell-to-cell adhesion [16].
1.1 Biological Model Assumptions
The main assumptions used in the present work are listed below:
1. Throughout the tumor, just two components occupy volume: parenchyma cells (of both phe-
notypes) and necrotic cells. We assume that the contribution to the volume from VECs is
negligible.
2. The tumor is partitioned into a viable region and, possibly, a necrotic core (if one forms).
The interface is identified as the surface where the limiting nutrient supply rate (Φ(v)) takes
a given critical value (here, Φ(v) < 0).
3. Tumor cells die only if the local density of nutrient is not sufficient to feed them, or as a result
of inter-phenotype competition for space.
4. Dead tumor cells may naturally disintegrate into waste products, mainly water.
5. Dead tumor cells do not actively move, but are subject to passive displacement via advection.
6. Dead tumor cells outside the tumor are phagocyted by macrophages.
7. Chemical factors naturally degrade.
8. Nutrients are mainly carried by the capillary network.
9. The density of all cell types are assumed to be the same.
10. Nutrient is absorbed by living tumor cells.
1.2 Model Formulation
Tumors are formed from the cell-to-cell adhesion of parenchymal cells and grow by cell mitosis [50].
Initially, when tumors are forming, they get all of their nutrients from the surrounding stroma [50].
As this tumor grows, having the nutrients diffuse into the tumor from the surrounding stroma is
no longer enough to support the growing mass and the tumor must grow its own vasculature to
support itself.
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Figure 1.1: Picture of a tumor spheroid taken using an electron microscope [41]
We consider a tumor growing in B(0, R(t)), the ball of radius R(t) in Rn, where n = {1, 2, 3}.
We choose this geometry because when tumors are forming they clump into spheroids, as seen
in Figure 1.1 [50]. Thus, using spherical symmetry for our model is a reasonable assumption.
Furthermore, we assume that the region is only occupied by parenchymal cells, i.e. no stroma is
found within the tumor. Tumors develop their own vasculature when they reach the critical radius
of approximately 1 mm [50]. This vasculature is formed when vascular endothelial cells (VECs)
combine with existing microvessels from the surrounding stroma and form new blood vessels in the
tumor [50]. The microvessels and VECs have a mass that is insignificant when compared to that of
the parenchymal cells, so in our model we track the total vasculature to measure the availability of
nutrients but do not take it into account when determining the mass of the tumor.
Tumors grow at a rate proportional to the net amount of mass created or lost through
the competing biological processes of mitosis and apoptosis giving them a changing boundary as
they evolve. Thus, tumors are natural candidates for mathematical problems described by a free
boundary. This boundary will change in time as the mass it surrounds evolves and thus our spatial
domain is time-dependent.
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We assume there is no background tissue in competition with the tumor cells for space or
nutrient. While this is a very strong assumption, it allows us to focus solely on the interplay between
these two competing processes in a regime where a nascent tumor has already displaced some small
amount of healthy tissue.
In his 2004 paper [36], Nagy developed a system of nonlinear ordinary differential equations
to model a heterogeneous primary neoplasm by tracking the mass of two different parenchyma
cell types, the mass of the vascular endothelial cells and the total length of microvessels. We
begin the formulation of our model by modifying Nagy's ODE system [36] to incorporate spatial
diffusion for the two different cancerous phenotypes and the endothelial cells, with densities denoted
respectively by u1, u2, and y; the local microvessel length density will be denoted by z and the
resource availability will be summarized in the single variable v. The time-dependent radius of
the tumor will be denoted by R(t). We modify the growth functions of u1 and u2 to incorporate
competition between the two types of parenchyma cells.
Table 1.1: Table of System Variables
Variable Meaning Units
ui Parenchymal cells of type i mass/volume
uN Necrotic cells mass/volume
y Vascular endothelial cells mass/volume
z Local microvessel length density length/volume
v Local resource concentration moles/mass
w Advective Velocity length/time
R Radius of tumor spheroid length
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Figure 1.2: Graphical description of model
Figure 1.2 describes the dynamics of the model and Table 1.1 define the variables used
in the system. The necrotic cells have a washout rate µN and are formed from the interspecies
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competition at rate b and/or from the limiting nutrient supply rate, Φi, becoming negative. The
parenchymal cells ui grow when the limiting nutrient supply rate, Φi, is positive. The local resource
concentration proxy variable, v, is affected directly by the mean microvessel length density, z, and
inversely by the local parenchymal cell density, ui. This dependence is given by (1.2). If v gets high
enough it also contributes to the growth of the VECs, y, which also washout at a rate β. The mean
microvessel length density, z, is directly affected by the concentration of VECs and by the washout
with the rate given in (1.9).
Let u1(s, t) and u2(s, t) be the mass density of parenchymal cells at time t and position s
with phenotypes 1 and 2, respectively. Define u(s, t) := u1(s, t) + u2(s, t), which is the total mass
density of the non-necrotic tumor cells. Then ui(s, t) and therefore u(s, t) take units mass/volume.
Nevertheless, these densities have no clear biological meaning, but their integrals do. For example,∫
A
u(s, t) ds, A ⊂ Ω
is the total mass of living tumor cells in a region A.
Furthermore, let y(s, t) be the mass density of immature vascular endothelial cells from
which mature blood vessels arise. Again, y(s, t) takes units mass/volume, and∫
A
y(s, t) ds, A ⊂ Ω
is the mass of VECs in region A.
Let z(s, t) be local microvessel length density at s and t. In the original model [36], this
quantity was denoted as v and was derived from the main dependent variables; here it arises
naturally as one of the modeled variables. Its unit is length/volume, and∫
A
z(s, t) ds, A ⊂ Ω
is the total length of microvessels in A. We scale z(s, t) such that normal tissue has z = 1.
We assume that blood vessels supply critical resources. The local resource concentration
C(s, t), is further assumed to be in quasi-equilibrium set by local vascular density, z(s, t). Let
Cm > 0 be the fixed concentration of resources in arterial blood with units mol/volume. Then we
assume
C(s, t) =
Cmz(s, t)
k + z(s, t)
(1.1)
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with k > 0 constant with the same units as z(s, t), namely length/volume. Therefore, C(s, t) has
the same units as Cm and we may write it as C(z).
Cancers cells also compete for resources locally. Therefore, we measure the mean resource
availability at point s ∈ Ω as the ratio
v(s, t) :=
C(z)
u(s, t) + ε
=
Cmz(s, t)
(u1(s, t) + u2(s, t) + ε)(k + z(s, t)
, (1.2)
where ε > 0 is incorporated so that the ratio does not become infinite when u(s, t) approaches 0.
We thus write v(u1, u2, z). Note that the meaning of v(u1, u2, z) is different than the meaning in
Nagy's model [36]. In that model v stood for the local resource concentration. In our model, v
stands for the local resource concentration per unit mass.
Local per capita tumor growth rates depend in part on local resource availability, v(u1, u2, z).
Let this dependency be represented by the function Φ(v), where we will suppress the arguments of v
for brevity. In general, we assume that Φ′(v) is everywhere positive for v ∈ [0,∞), saturating (that
is, Φ→ Φmax as v →∞, with Φmax a constant) and Φ(0) ∈ (−∞, 0) since in general more resources
means more proliferation and less death [36]. Units of Φ are 1/time. In our implementation we
use the Gammack et al. model [22], which was also applied in the 2004 ODE model to govern the
dynamics of the ith phenotype:
Φi(v) =
Aiv
2
cˆ21i + v
2
−Bi
(
1− v
2
cˆ22i + v
2
)
. (1.3)
Values for parameters Ai, Bi, cˆi1, cˆi2 can be obtained empirically and are found in [22] and [48].
Local per capita growth rate also depends on crowding, measured directly by local cell
density, u(s, t). In other words, space is also a resource (c.f. Assumption 3 in 1.1). Biologically,
this assumption is justified by observations in vitro and in vivo [50]. Although it is well-known
that transformed cells often lack the contact inhibition characteristic of "healthy" cells, as bulk
pressure inside regions of cell culture and tumors increases due to cell proliferation in a confined
space, mortality of transformed cells also increases. In addition, tumor cells are known to acidify
their local environment. Local acidification also increases mortality rate. Experiment and clinical
observation also shows that phenotypes within the tumor vary in their acidification ability and in
their tolerance to the acid environment. Therefore, phenotypes affect the local "carrying capacity"
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of other phenotypes around them, and different phenotypes may not experience the same social
growth retardation in the same location.
Cancer cells move. They move seemingly randomly, in response to chemical gradients,
both soluble and fixed in the matrix, and due to advection. We also assume tumor tissue to be
homogeneous with respect to diffusion, i.e., the diffusion coefficient is constant (c.f. Assumptions
1, 3, 9, and 10 in 1.1).
Necrotic cells do not move, but are subject to passive displacement via advection. They can
either naturally disintegrate into waste products or be phagocyted by macrophages if they are on
the boundary of the tumor mass (c.f. Assumptions 1, 3, 4, 5, 6, 9, and 10 in 1.1). We combine all
of these rates into a single constant, µN , with units given in Table 1.3.
All these considerations lead to the following growth equations for the tumor mass:
∂ui
∂t
= (Φi(v)− buj)ui −∇ · (w ui) + di∆ui, i, j ∈ {1, 2}, i 6= j (1.4)
∂uN
∂t
+∇ · (w uN ) =
∑
i
(buiuj + Φ
−
i ui)− µNuN i, j ∈ {1, 2}, i 6= j, (1.5)
where b and di are nonnegative constants representing between-phenotype competition and the
diffusion constant, respectively. The vector w represents the advective radial velocity as a function
of time and position satisfying w(0) = 0. The function Φi − buj is the overall "growth" term for
ui, thus ui will either increase in density or necrose depending on the sign. Parameter b has units
per mass per time, and di have units length
2/time whose values have an upper limit determined in
[46], the units for Φi are given in Table 1.2.
Cancer cells activate angiogenesis by secreting a signal that either directly or indirectly
simulates endothelial cells to migrate to the site of origin to the signal, differentiate, and organize
into functional microvessels [50]. The strength of this signal depends on local resource availability,
v(s, t). We assume that the different phenotypes vary in their ability to generate this signal. Let
hi(v) be the signal strength of the ith phenotype experiencing an environment with local resource
availability v(s, t). For now we assume the following form for h(v) because it matches the qualitative
picture obtained from experiments in [30, 45]:
hi(v) = ζive
−ξv. (1.6)
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The nonnegative constant ζi is the ith phenotype's general angiogenic effectiveness, and the positive
constant ξi determines the resource availability at which the ith phenotype maximizes its angiogenic
signal. Specifically, hi(v) is maximized at v = 1/ξi. Biologically, h
′(v) < 0 for all v > 1/ξ because
cells "turn the signal down" as resources become increasingly available. On the other hand, h′(v) > 0
for v ∈ [0, 1/ξ) because at such low resource availability, cells become physiologically stressed to
the point where their ability to generate the signal becomes impaired [30, 50]. Genes for certain
important angiogenic signaling molecules, including vascular endothelial growth factor (VEGF),
basic fibroblastic growth factor (bFGF), and platelet-derived growth factor (PDGF-β), appear to
have a mechanism which allows expression even when hypoxia becomes severe [45].
Because of the complexity of the angiogenic signal, the units of the signal strength h(v) are
arbitrary. Therefore, the units of ζ are "signal units" × mass × volume/mol, and those of ξ are
mass × volume/mol.
Signal strength at location s and time t is assumed to be a weighted average of the signals
produced by cells at that location. Therefore, the signal strength at point s and time t, which we
denote H(u1, u2, v), is
H(u1, u2, v) =
u1(s, t)h1(v) + u2(s, t)h2(v)
u1(s, t) + u2(s, t)
. (1.7)
Local signal strength H(u1, u2, v) therefore has the same units as the hi(v).
This angiogenic signal stimulates VEC proliferation. We assume that the signal initiates
proliferation at basic rate α, which has units per "unit signal" per time. Immature vascular en-
dothelial cells both mature and die at constant per capita rates [30, 50], which we combine into a
single rate parameter β, with units per time (c.f. Assumption 7 in 1.1). VECs disappear by either
dying or incorporating themselves into a growing blood vessel [50]. These, and the assumptions
of the angiogenesis signal proliferation and homogeneous random diffusion of VECs leads to the
following model of VEC dynamics:
∂y
∂t
= (αH(u1, u2, v)− β) y(s, t) + d∆y(s, t). (1.8)
We assume that microvessels arise from the VEC population. They do so at per capita rate
γ, with units length per mass per time. Since β represents the maturation rate of VECs and also
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their death rate, we must have γ ≥ β. Existing microvessels are also remodeled, as described in [36].
In addition, we can also add a mortality rate associated with cell density, since we know that vessels
collapse under pressure, which causes their resorption [9, 10, 5, 29]. As a first approximation we
assume that this pressure-induced mortality is proportional to tumor size, say η
√
R(t) + , where
η is a nonnegative constant with units volume per mass × time and  is a fixed small positive
constant . Estimates for η are derived from the work of Jain et al. [5, 10, 29] since research has
shown that microvessels deteriorate due to intratumor pressure [49]. Microvessels cannot move.
These assumptions yield the following model:
∂z
∂t
=
γ
1 +R2(t)
y(s, t)− δz
2(s, t)
u(s, t)
− η
√
R(t) + ε z(s, t), (1.9)
where δ is a positive constant with units mass per length × time. The coefficients γ
1+R2(t)
and
η
√
R(t) +  are chosen based on reasonable assumptions about cancer growth. There is very liter-
ature describing the decrease in vascularization as we move from the boundary towards the center
of the tumor stemming from the increased pressure in the interior of the tumor. These particular
functions were chosen so that the tumor does not die out immediately in our simulations.
Necrosis occurs when there is not sufficient vascular supply to a region of a tumor. It is
a common feature in certain kinds of tumors that have grown to a significant size [50]. Because
of this, it has been a feature of many mathematical models of cancer [7, 19, 14, 28, 27]. In our
model, the lower y is the more likely there is to be necrosis in that region (c.f. Assumption 8 in
Section 1.1). We numerically define necrosis to occur for ui in the region where Φi < 0. This is
because cells have a stronger growth dependence on blood supply than they do from any spatial
constraints [22]. Choosing Φi < 0 means that cells are dying and this is what we define as necrosing
(c.f. Assumption 2 in 1.1).
Table 1.2: Table of Functions
Function Meaning Units Ref.
Φi Local per capita growth rate of cell type i 1/time [22]
hi Angiogenesis signal strength of cell type i Signal strength units
∗ [1]
H Mean angiogenic signal strength Signal strength units∗ [1]
γ
1+R2(t)
VEC recruitment rate 1/gm/day Assumption
η
√
R(t) +  Pressure-induced microvessel decay rate ml·length/gm·day Assumption
B(0, R(t)) Ball of radius R(t) in Rn length Assumption
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1.3 Advection Speed
To calculate the advection velocity w, we make the assumption that u1 + u2 + uN ≡ u∗, where u∗
is a constant we later choose to be 1 so uN is the volumetric fraction of necrotic cells permanently
or temporarily in the tumor. We shall assume that necrotic cells only move via advective flow, do
not diffuse, and that their degradation rate µN is independent of the density of parenchymal cells
(when µN = 0 the dead cells remain permanently). Then,

∂u1
∂t
+∇ · (w u1)− d1∆u1 = Φ+1 u1 − Φ−1 u1 − bu2u1,
∂u2
∂t
+∇ · (w u2)− d2∆u2 = Φ+2 u2 − Φ−2 u2 − bu1u2,
∂uN
∂t
+∇ · (w uN ) =
∑
i
(buiuj + Φ
−
i ui)− µNuN i, j ∈ {1, 2}, i 6= j,
(1.10)
where Φ+i and Φ
−
i are the positive and negative parts of Φi, respectively. To calculate w we exploit
u1 +u2 +uN ≡ u∗, sum the three equations in (1.10), and use ∇· (wui) = w ·ui+ui∇·w to obtain
u∗∇ ·w − d1∆u1 − d2∆u2 =
(∑
Φ+i ui
)
− µNuN ,
which can be rewritten as
u∗∇ ·w = d1∆u1 + d2∆u2 +
(∑
Φ+i ui
)
− µNuN ,
and, integrating over B(0, r) on the left-hand side,
u∗
∫
B(0,r)
∇ ·wdr = u∗
∫
∂B(0,r)
w · dS = u∗w(r, t)|Sn(r)|.
Here we have used the radial symmetry to replace the vector w(r, t) by its constant magnitude
w(r, t) on the boundary of the ball multiplying the outward unit normal vector n. As for the
right-hand side, we have
d1
∫
B(0,r)
∆u1 dr +
∫
B(0,r)
d2∆u2 dr +
∫
B(0,r)
(∑
Φ+i ui
)
− µNuN dr
= d1
∫
∂B(0,r)
∇u1 · n dS + d2
∫
∂B(0,r)
∇u2 · n dS +
∫
B(0,r)
(∑
Φ+i ui
)
− µNuN dr,
where ∇u1 · n is the outward unit normal derivative of u1.
12
Hence,
w(r, t) =
2∑
i=1
di
u∗
∫
∂B(0,r)
∇ui · n dS +
∫
B(0,r)
(∑
Φ+i ui
)
− µNuN dr. (1.11)
The boundary at R(t) moves just like the cells, so that R˙(t) = w(R, t) :
R˙ =
2∑
i=1
di
u∗
∫
∂B(0,R(t))
∇ui · n dS +
∫
B(0,R(t))
(∑
Φ+i ui
)
− µNuN dr.
which, after applying the boundary conditions at r = R(t), gives
R˙ =
1
|Sn(r)|
∫
B(0,R(t))
(∑
Φ+i ui
)
− µNuN dr. (1.12)
Now the integral on the right hand side represents the net new volume created/lost and,
therefore, upon division by the surface area of the n-ball of radius R must equal the rate of change
of R.
To summarize, by combining the equations (1.4), (1.8), (1.9), (1.10), and the functions (1.2),
(1.3), (1.6), (1.7), (1.11) lead to the following system we wish to consider:

∂ui
∂t
= (Φi(v)− biuj)ui(s, t)−∇ · (wui(s, t)) + di∆ui(s, t), i, j ∈ {1, 2}, i 6= j,
∂y
∂t
= (αH(u1, u2, v)− β)y(s, t) + dy∆y(s, t),
∂z
∂t
=
γ
1 +R2(t)
y(s, t)− δz
2(s, t)
u(s, t)
− η
√
R(t) +  z(s, t),
uN = u
∗ − u1 − u2,
w(r, t) =
2∑
i=1
di
u∗
∫
∂B(0,r)
∇ui · n dS +
∫
B(0,r)
(∑
Φ+i ui − µNuN
)
dr
R˙ =
1
|Sn(r)|
∫
B(0,R(t))
(∑
Φ+i ui
)
− µNuN dr
Φi(v) =
Aiv
2
cˆ21i + v
2
−Bi
(
1− v
2
cˆ22i + v
2
)
,
H(u1, u2, v) =
u1(s, t)h1(v) + u2(s, t)h2(v)
u1(s, t) + u2(s, t)
, hi(v) = ζive
−ξv,
u(s, t) = u1(s, t) + u2(s, t), v(s, t) =
Cmz(s, t)
u(s, t)(k + z(s, t))
(1.13)
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with initial and boundary condition
Q(s, 0) = Q0(s), s ∈ Ω(t)
∂Q(s, t)
∂n
= 0, s ∈ ∂Ω(t)
(1.14)
where Ω(t) = B(0, R(t)) is the ball in Rn, n = {1, 2, 3}, and ∂∂n is the unit normal derivative. For
simplicity, in (1.14) we mean Q = (u1, u2, y, z) and Q0 is the initial condition for (u1, u2, y, z).
When we derived the equation for w (1.11), we did it in spherical coordinates in order to
have a general formula for any coordinate system with radial symmetry. While this allows for a
more complete model, this complicates the numerics because of the 1/r2 terms in the equation. To
simplify the numerics, we consider the one-dimensional version, thus we solve the system on the
line [0, R(t)] instead of on the sphere. Rewriting the Laplacian on the line and modifying the initial
and boundary conditions (1.14) reduces our model to the following system:

∂ui
∂t
= (Φi(v)− buj)ui − ∂
∂r
(wui) + di
∂2ui
∂r2
, i, j ∈ {1, 2}, i 6= j
∂y
∂t
= (αH(u1, u2, v)− β) y + dy ∂
2y
∂r2
∂z
∂t
=
γ
1 +R2(t)
y − δz
2
u+ ε
− η
√
R(t) +  z
v(r, t) =
Cmz(r, t)
(u(r, t) + ε)(k + z(r, t))
(1.15)
with initial and boundary conditions
Q(r, 0) = q0(r), r ∈ [0, R)
∂Q(R, t)
∂r
= 0
∂Q(0, t)
∂r
= 0
(1.16)
where, for simplicity, by Q in (1.16) we mean Q = (u1, u2, y, z) and Q0 is the initial condition for
(u1, u2, y, z). The homogeneous Neumann boundary condition is required by the assumption that
the domain contains all the parenchyma and vascular endothelial cells and nothing else.
We take as natural units millimeters for length, days for time, centigrams for mass, and
milliliters for volume. Cancer cells have a density approximately equal to that of water (1gm/mL)
[50]. The values for the parameters used in the system are found in Table 1.3
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We use a similar initial condition as in [36] but assume instead that u2 is nonzero in a small
spherical region compared to u1, which is positive on the whole domain. The vascularization of
a tumor should be higher as it gets closer to the outer edge of the tumor [44], thus the variable
y should have a higher initial value near the core of the tumor and decrease its value since less
microvessels means more angiogenesis signaling [50].
In order to solve the problem (1.15), (1.16), and (1.12) first we make a change of variable to
fix the domain Ω(t) to be the unit ball for all time, and thus get rid of the free boundary problem and
replace it with a fixed boundary problem [17]. Using the new variable r˜ = r/R(t) and the chain rule
to calculate the partial derivatives in (1.15) and (1.16) we arrive at the new model (after dropping
the tildes) for the case of one spatial dimension, which we explore in more detail in Chapter 2, we
have 
∂ui
∂t
= (Φ1(v)− buj)ui − 1
L(t)
∂
∂r
(wui) +
di
L2(t)
(
∂2ui
∂r2
)
+
rL˙(t)
L(t)
∂ui
∂r
∂y
∂t
= (αH(u1, u2, v)− β) y + dy
L2(t)
(
∂2y
∂r2
)
+
rL˙(t)
L(t)
∂y
∂r
∂z
∂t
=
γ
1 + L2(t)
y − δz
2
u+ ε
− η
√
L(t) +  z+
rL˙(t)
L(t)
∂z
∂r
v(r, t) =
Cmz(r, t)
(u(r, t) + ε)(k + z(r, t))
w(r, t) =
d1
u∗L(t)
∂u1
∂r
+
d2
u∗L(t)
∂u2
∂r
+
L(t)
u∗
∫ r
0
(∑
i
Φ+i ui − µNuN
)
dr˜
L˙(t) = L(t)
∫ 1
0
(∑
i
Φ+i ui − µNuN
)
dr˜
(1.17)
with the same boundary condition (1.16). In the system above, L(t) represents the length of a
one-dimensional tumor at time t. However, the systems (1.17) and (1.15) are equivalent and thus
any result about (1.17) automatically applies to (1.15) [12].
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Table 1.3: Parameters and their default values
Parameter Meaning Value Units Ref.
Ai Max Proliferation rate of phenotype i .06 day
−1 [22, 48]
Bi Basic Mortality of phenotype i .06 day
−1 [22, 48]
cˆ1i Resource sensitivity (proliferation) 0.8 mol/µL/gm [22, 48]
cˆ2i Resource sensitivity (mortality) 0.4 mol/µL/gm [22, 48]
b Cell packing constraint .0004 gm−1 day−1 Assumption
di Cell diffusion constants 1× 10−5 cm2/day [46]
Cm Serum resource concentration 95 mmHg [22]
k Resource delivery parameter 1.375 length∗/µL [22]
ζ Angiogenesis signal parameter 0.4 (U·gm·mL/mmHg)∗∗ [30]
ξ Angiogenesis peak parameter 0.06 gm·mL/mmHg [30]
α VEC proliferation response 0.06 (U−1)∗∗ day−1 [36]
β VEC disappearance rate 0.04 day−1 [36]
γ VEC maturation rate 4 length∗/gm/day [36]
µN Necrotic wash-out rate 0.0005 /gm/day Assumption
δ Microvessel remodeling rate 0.004 cgm/length∗·day [30]
η Microvessel collapse rate .006 ml/gm·day [5, 10, 29]
1
1∗Scaled in microvessel length units such that for normal tissue, z = 1.
∗∗U stands for angiogenesis signaling units.
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Chapter 2
NUMERICAL METHODS
In Chapter 1 we derived our model of cancer. In this chapter we cover the numerical methods used
to solve the system (1.17), (1.12), and (1.16) as well as provide numerical results about stability.
The main tool for simulating this model is MATLAB, but we have written our own numerical
scheme using finite difference methods to solve the system. We use a "divide and conquer" method
seen in the work done in the field operator splitting to separate the growth of the radius (1.12)
from the system of PDEs (1.17) and combine their solutions before the end of the time-step [24].
In other words, at time tn+1, we first solve for the radial growth using the values at u
n then use
the length, L(tn+1), to solve for the solution of the system u
n+1.
The inter-species competition coefficient, b, is generated randomly for each simulation. The
inter-species competition should be the same for each phenotype since there should not be a dif-
ference with how phenotype 1 interacts with phenotype 2 versus how phenotype 2 interacts with
phenotype 1. The b's are generated randomly on the interval [.0002, .0004] in each simulation. The
rest of the parameter values are all fixed at the values given in Table 1.3.
2.1 Finite Difference Scheme
To solve the system (1.17), we use an implicit method numerical scheme to get the solution at
the following time step. We approximate the time derivative using a first-order forward difference
scheme and the spatial derivatives using second-order central differences. In other words, we have
ut ≈ u
n+1
k − unk
∆t
and
ur ≈
un+1k+1 − un+1k−1
2∆r
, urr ≈
un+1k+1 − 2un+1k + un+1k−1
∆r2
17
Thus, the system, (1.17), when written using these difference schemes becomes
un+1i,k − uni,k
∆t
= (Φi − bunj,k)un+1i,k −
∂wnk
Ln+1
un+1i,k −
1
Ln+1
wnk
[
un+1i,k+1 − un+1i,k−1
2∆rn
]
+
1
L2n+1
[
un+1i,k+1 − 2un+1i,k + un+1i,k−1
∆r2n
]
+
rL˙n+1
Ln+1
[
un+1i,k+1 − un+1i,k−1
2∆rn
]
, i, j ∈ {1, 2}, i 6= j
yn+1k − ynk
∆t
= (αH − β)yn+1k +
1
L2n+1
[
yn+1k+1 − 2yn+1k + yn+1k−1
∆r2n
]
+
rL˙n+1
Ln+1
[
yn+1k+1 − yn+1k−1
2∆rn
]
zn+1k − znk
∆t
=
γ
1 + L2n+1
ynk −
δznk
un1,k + u
n
2,k + ε
zn+1k − ηzn+1k +
rL˙n+1
Ln+1
[
zn+1k+1 − zn+1k−1
2∆rn
]
,
(2.1)
where Ln := L(tn), the length of the interval at time tn, and the ∂w
n
k term is calculated with a
similar forward difference formula as above applied to (1.11) but instead of using a finite difference
for the integral in the equation, we evaluate the integrand using the known solution at time tn by
the fundamental theorem of calculus. ∆rn is the mesh at time tn and is, initially, equally spaced
with 101 points on the interval [0, 1]. To solve equation (1.12) for L(t), we use a first-order forward
difference formula and calculate the integral using a trapezoidal rule with the functions in the
integrand being evaluated at time tn. To add additional points to the mesh we track a subset of
the {tk} starting with t0. Whenever the difference between L(tj)− L(tk) > 0.01, j > k, we add an
additional point on the mesh and then use the size of the radius at tj as our reference for future
iterations. We do not delete points from the mesh if the radius shrinks.
Solving the system (2.1) for all of the terms with tn+1 yields a matrix equation of the form
AUn+1 = Un, (2.2)
where A is a tridiagonal matrix of size 4M × 4M , M representing the number of mesh points,
the vector Un is the solution at time tn, and U
n+1 is the unknown solution at time tn+1. The
subdiagonal, diagonal, and superdiagonal entries for each variable of A are, respectively,
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ui

rL˙n+1∆t
2Ln+1Drn
− di∆t
(Ln+1∆rn)2
− ∆tw
n
k
2Ln+1∆rn
1− (Φi − buj)∆t+ 2di∆t
(Ln+1∆rn)2
+
∆t
Ln+1
∂wnk
−rL˙n+1∆t
2Ln+1Drn
− di∆t
(Ln+1∆rn)2
+
∆twnk
2Ln+1∆rn
, i, j ∈ {1, 2}, i 6= j,
y

rL˙n+1∆t
2Ln+1Drn
− dy∆t
(Ln+1∆rn)2
1− (αH − β)∆t+ 2dy∆t
(Ln+1∆rn)2
−rL˙n+1∆t
2Ln+1Drn
− dy∆t
(Ln+1∆rn)2
,
z

rL˙n+1∆t
2Ln+1∆rn
1 +
δznk∆t
un1,k + u
n
2,k + ε
+ η∆t
−rL˙n+1∆t
2Ln+1∆rn
.
(2.3)
Applying the boundary conditions (1.16) to (2.3) is done by modifying the first and last entry of A
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for each variable. The right hand side of (2.2) is
uni =

0
uni,2
...
uni,M−1
0

, i, j ∈ {1, 2}, i 6= j,
yn =

0
yn2
...
ynM−1
0

,
zn =

0
zn2 +
γ
1+L2n+1
yn2
...
znM−1 +
γ
1+L2n+1
yM−12
0

,
(2.4)
so we haveUn = (un1 ,u
n
2 ,y
n, zn)T for (2.2) and each zero in (2.4) represents the Neumann boundary
condition for each variable.
2.2 Convergence of Numerical Scheme in The Case of a Prescribed Solution
In order to demonstrate the convergence of the numerical scheme, we rewrite the differential equa-
tions in our model (1.13) in the form Lu = 0 for the appropriate differential operator L, and then
add on the right-hand side the "load" term given by Lue, where ue is the prescribed solution we
want to approximate. Thus, we replace the original homogeneous system by a non-homogeneous
one whose analytical solution is the prescribed ue. Then we use the numerical scheme (modified
to include the obvious terms corresponding to the nonzero right-hand side) to find an approximate
solution uapprox and compute the error in the approximation by taking the difference between ue
and uapprox at all the time-space grid points. For ease of notation in this section, we shall call
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{ue1, ue2, ye, ze} = ue. If we want the system (1.17) to have solution
uei = L
i+1(t)(1− r)i+1, (2.5)
(where for i = 3, 4 we mean ye, ze, respectively) then we make appropriate changes to the right
hand side of (1.17) so that the system converges to the solution ue.
By modifying (2.1) slightly, the system (2.6) will have solution ue. To do this, we add a few
terms to the right-hand side of (2.1), which yields the following system of equations
un+1i,k − uni,k
∆t
= (Φi − bunj,k)un+1i,k −
∂wnk
Ln+1
un+1i,k −
1
Ln+1
wnk
[
un+1i,k+1 − un+1i,k−1
2∆rn
]
+
1
L2n+1
[
un+1i,k+1 − 2un+1i,k + un+1i,k−1
∆r2n
]
+
rL˙n+1
Ln+1
[
un+1i,k+1 − un+1i,k−1
2∆rn
]
+(i+ 1)Lin+1L˙n+1(1− r)i
−(Φi − buej)uei + ∂weuei − we(i+ 1)Li+1n+1
−dii(i+ 1)Li+1n+1(1− r)i−1, i, j ∈ {1, 2}, i 6= j
yn+1k − ynk
∆t
= (αH − β)yn+1k +
1
L2n+1
[
yn+1k+1 − 2yn+1k + yn+1k−1
∆r2n
]
+
rL˙n+1
Ln+1
[
yn+1k+1 − yn+1k−1
2∆rn
]
+4L3n+1L˙n+1(1− r)3 − (αH − β)ye − 12d3Li+1n+1(1− r)2
zn+1k − znk
∆t
=
γ
1 + L2n+1
ynk −
δznk
un1,k + u
n
2,k + ε
zn+1k −
√
Ln+1ηz
n+1
k
+
rL˙n+1
Ln+1
[
zn+1k+1 − zn+1k−1
2∆rn
]
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1 + L2n+1
ye − δ(z
e)2
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e
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−
√
Ln+1ηz
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(2.6)
with new initial and boundary conditions
ui(r, 0) = (1− r)i+1, r ∈ [0, 1)
∂u(0, t)
∂r
= −(i+ 1)(1− r)i
∂u(1, t)
∂r
= 0.
(2.7)
Now, it remains to find the order with which the numerical method (2.6) converges to (2.5).
To do so, we find a constant, p, such that
||uh − ue|| = Chp
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where h = ∆r = ∆t∆t+2 and C > 0 is a constant. Another way to calculate p is by finding the ratio
of ||uh − ue|| to ||uh/2 − ue|| which yields
||uh − ue||
||uh/2 − ue||
= 2p,
and thus
log2
∣∣∣∣ ||uh − ue||||uh/2 − ue||
∣∣∣∣ = p.
The table below gives the values used and the average p for ue.
∆t ∆r p
0.1 .0476 0.72
.05 .02439 0.80
.025 .01235 0.88
.0125 .00621 0.93
.00625 .00311 0.96
.003125 .00155 0.99
.001562 .000775
Table 2.1: Comparison of p values for different step sizes.
The end time for all of the simulations in Table 2.1 is 1000 days (∼ 3 years), thus we are
confident any simulation up to 1000 days is numerically stable. We suspect simulations past 1000
days should be stable as well, but, to minimize computing time, we ended all of the simulations in
Chapter 3 after this time period. We also added mesh points as needed according to the scheme
we used in Section 2.1, so the convergence result using operator splitting is for the system with a
moving boundary, not just a fixed domain.
Additionally, we investigate the changes in the solution with decreasing values of ∆t to
determine what effects, if any, increasing the number time steps has on the solution. Table 2.2 has
the values of ∆t on the left and in between the values of ∆t, on the right, are the values of the `∞-
norm of the differences. For example, the first value of column u1 is the value of ||u1,∆t1−u1,∆t2 ||∞,
evaluated on the larger mesh since u1,∆t1 and u1,∆t2 coincide on those mesh points. It can be seen
that as ∆t decreases, there is no significant change in the error to the solution. Thus, we feel that
using ∆t = 0.1 is reasonable and reduces the computation time.
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∆t u1 u2 w y z
0.1 4.397e-4 4.295e-4 4.611e-6 5.580e-5 1.001e-3
.05 1.980e-4 1.957e-4 4.105e-6 2.935e-5 4.855e-4
.025 7.512e-5 6.941e-5 3.849e-6 1.247e-5 2.954e-4
.0125 3.950e-5 4.038e-5 2.352e-6 8.191e-6 9.339e-5
.00625
Table 2.2: Comparison of solution norms for different values of ∆t.
In conclusion, because of the results in both tables 2.1 and 2.2 we are confident that the
differential system with the given load (2.6) and prescribed known solution (2.5), the numerical
method converges with first order accuracy. This leads us to believe that the numerical method
(2.1) without the load, Lue, for the differential system (1.17) will also converge with first order
accuracy.
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Chapter 3
SIMULATIONS
In 2004 Nagy hypothesized, but did not explore, that heterogeneous tumors would behave more like
ecological systems than integrated tissues when taking into consideration the dynamics of spatial
movement on the system [36]. Additionally, the hypertumor mechanism has been hypothesized to
be a cause of the necrosis observed in many vascularized tumors [36, 40]. In our attempt to answer
these questions using simulations, we find both necrotic tissue forming, as well as polymorphic
tumors with both niche segregation, albeit incomplete - though indicative of the behavior of the
tumor for longer time-scales, as well as tissue integration. We are primarily interested in three
different cases for the growth functions Φi; the Φi's cross each other and either the mutant or
resident strain has a higher growth rate in the hypoxic region while the other strain is a better
grower in the normoxic region, and when Φ2(v) > Φ1(v) for all v. The subcases are related to the
angiogenesis signaling for each strain (hi). (Note to reader: The density graphs - green and gray
color scheme - are plotted so that the the sum of u1 and u2 are shown and any whitespace is the
local density of necrosing cells. For example, if for some point, r˜, the top of the gray curve reaches
0.3, the green curve plotted on top reaches 0.8, and the whitespace covers the rest up, then the
mutant strain has 30% of the local density, the resident strain has 50% of the local density, and the
necrosing cells cover the remaining 20% of the density at that point.)
In Figure 3.1 the mutant strain has a higher proliferation rate than the resident strain when
below v ≈ 42, lower proliferation rate when v > 42, and has a lower angiogenic signaling rate than
the resident strain for all v. The tissues segregate, albeit incompletely, into distinct niches as was
hypothesized by Nagy [36]. Furthermore, the mutant strain is unable to successfully invade the
tumor tissue (in our 1000 day time scale) towards the center because the vascularization is higher
in that region - the mutant strain is favored in normoxic regions - and the advective flow moves
the mass away from the center. A similar pattern is observed when the mutant strain forms on the
outer edge of the tumor; c.f. Figure 3.2.
The mass of the tumor taken up by the resident strain varies depending on where the mutant
strains form. The closer the mutant strain is to the core, the more likely the mutant strain is to
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Figure 3.1: The mutant strain is able to invade but not completely. Parameters different than Table
1.3 are A1 = .02, A2 = .04, d2 = 2× 10−5, ξ1 = 0.04, ξ2 = 0.01
invade completely and wipe out the resident strain. The size of the tumors at the end of simulation
also vary depending on the location of the mutant, and we believe that this is due to the ability
to invade the tumor outwardly versus inwardly because of advection. In Figure 3.3 we observe
how much the location of the mutant affects the mass of the tumor it has invaded as well as the
difference at end-of-simulation tumor size. Surprisingly, angiogenic cheaters slow down the growth
of the tumor depending on their proximity to the outer edge; the closer the mutant is to the edge,
the slower the tumor will grow. We believe this is an area worthy of further investigation since it
hints at the possibility that the hypertumor mechanism may be the cause of the 'fingering' patterns
observed in non-spheroid tumors.
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Figure 3.2: The mutant strain forms on the edge and invades slower. Parameters different than
Table 1.3 are A1 = .02, A2 = .04, ξ1 = 0.04, ξ2 = 0.01
On the other hand, if the mutant strain has a slower growth rate than the resident strain
when the tumor is in a hypoxic state, has a higher angiogenic signaling rate than the resident strain,
then the tumor behaves locally like integrated tissue; c.f. Figure 3.4 and 3.5. We hypothesize that
the tissue integration of parenchymal cells occurs because the resident strain forms a parasitic
relationship on the mutant strain by piggy-backing off the mutant strain's increased angiogenic
signaling capabilities. In this scenario, neither strain will drive the other to extinction nor will they
separate into distinct niches since the mutant strain is unable to out-compete the resident strain
and the resident strain benefits from its parasitic relationship with the mutant strain. Additionally,
for the tumor size, this parasitic relationship leads to larger tumors than if the resident alone were
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Figure 3.3: Comparison of invasion based on location of mutant. Parameters different than Table
1.3 are A1 = .02, A2 = .04, ξ1 = 0.04, ξ2 = 0.01
present because of the added vascularization, and thus mass, that is formed in the tumor. There is
no appreciable difference in size with regards to where the mutant strain forms.
If, under the same conditions as Figure 3.5 and 3.4, the mutant strain forms on the edge,
the mutant strain goes extinct but there is no change in tumor size versus a tumor with only the
resident strain. The extinction is due to the added intratumoral pressure from the tumor size that
decreases vascularization.
The hypertumor mechanism described in [36] has the most noticeable effect on tumorigenesis
whenever the following conditions are met: the mutant strain has a more aggressive growth rate
than the resident regardless of the local resource density available, the mutant focuses almost all
of its resources to proliferating and very little to angiogenic signaling, and is formed near the core
(c.f. Figure 3.6). When these three conditions happen, the mutant invades, becomes necrotic, and
eventually dies since it is unable to sustain itself due to its reduced ability to form new vasculature.
There is evidence to suggest that in the region of necrosing tissue a palisading effect occurs, but
further investigation is needed to fully understand this phenomena [50]. We caution that in Figure
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Figure 3.4: The resident strain benefits from increased angiogenic signaling by the mutant strain;
the mutant strain forms in the middle of the tumor. Parameters different than Table 1.3 are
A1 = .04, A2 = .02, ξ1 = 0.01, ξ2 = 0.04
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Figure 3.5: The resident strain benefits from increased angiogenic signaling by the mutant strain;
the mutant forms at the core. Parameters different than Table 1.3 are A1 = .02, A2 = .04, ξ1 =
0.04, ξ2 = 0.01
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Figure 3.6: The mutant strain invades, forms a hypertumor, and eventually will die if it cannot
produce enough new vasculature.
3.6 the mutant strain can provide enough vasculature for itself in the time-scale used in simulation,
so this is not a true hypertumor. Running simulations on a longer time scale or completely shutting
off the mutant strain's angiogenic signaling capabilities will definitively answer this question.
When the mutant forms in the middle, the tumor reduces drastically in size after the death
of the mutant, but does not go extinct. The tumor segregates into a regions with the resident
strain and mutant residing in distinct niches. Our model predicts that the hypertumor forms a
necrotic ring around the resident strain, essentially cutting it off, but not eliminating, the tumor;
c.f. Figure 3.8. In this scenario it is possible that the resulting tumor is no longer a threat to
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Figure 3.7: The formation of a necrotic core. Once a necrotic core is formed it will permanently be
there.
the host depending on the size of the resident strain. The total vascularization is increasing in the
region with the resident strain but decreasing, and thus eventually wiping out the mutant cancer
cells, in the region with the mutant strain; c.f. Figure 3.8
If the resident strain has a higher proliferation rate with respect to the nutrient availability,
i.e. the growth functions, Φi, do not cross, then the resident strain will always wipe out the mutant
regardless of how much angiogenic signaling is provided by the mutant. This is because our initial
assumptions about the resident strain is that it will provide enough vasculature for itself in absence
of the mutant strain; i.e., it will out-compete the mutant and drive it to extinction.
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Figure 3.8: The mutant strain invades, forms a hypertumor, and reduces the final tumor size.
The simulations above all had an initial concentration of 0.2 cg/mL for the mutant parenchy-
mal strain. Since this may be seen as an already established strain, we show simulations that start
with an initial concentration of 0.02 cg/mL do not go extinct. Thus, the simulations previously
shown are all viable and are shown instead of the simulations with the smaller initial concentra-
tion due to the time it takes for the simulation to end. Figure 3.11 shows the simulations for the
decreased initial value for the mutant strain.
Biological studies show that if a large enough tumor cannot maintain its vasculature the
tumor will necrose [50]. Thus, we investigate numerically to find the constant initial values of
u1, u2, y, z that will drive the tumor to extinction. We note that by extinction of the tumor, we are
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Figure 3.9: The formation of a necrotic ring around the resident strain. The hypertumor encloses
the resident strain but does not eliminate it from the tumor, possibly reducing the tumor size after
the necrotic cells are phagocyted.
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Figure 3.10: The invasion of the mutant strain in the hypertumor. It closes off the resident strain
but does not eliminate it. The yellow line between the blue and red is the barrier formed by
necrosing cells.
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Figure 3.11: Simulations showing the final size of the tumor when u2 = 0.02.
referring to the equilibrium of the system corresponding to (u¯1, u¯2, u¯N , y¯, z¯, R¯) = (0, 0, 1, 0, 0, 0) :=
E0, since in order to satisfy the assumption u1 + u2 + uN = 1, we must have uN = 1. Even though
we do not have a rigorous proof that E0 is locally asymptotically stable, our simulations suggest
that if yz ≤ η2γ the tumor is unable to recover from its hypoxic state by the time the simulation
is over, and seems to eventually become completely necrotic. Figure 3.12 shows the end result for
one such scenario and taking note of the y-axis scaling, the tumor is almost entirely composed of
necrotic cells. We find it reasonable to assume that any tumor that reaches this level of density will
eventually be driven to extinction and it is only a matter of time until the tumor shrinks to zero if
we ran the simulations longer.
35
Figure 3.12: A necrotic tumor after 1000 days
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Chapter 4
CONCLUSION AND FUTURE WORK
In Chapter 2 we implemented a numerical method to solve our system of equations; showed that
the numerical scheme used converges to a known special solution and is valid for the time-scales
used in Chapter 3; and numerically explored the stability of the equilibrium. We still feel that this
area can be improved upon, in particular in showing that the numerical scheme is valid for longer
time scales. We are interested in investigating longer time scales because Nagy conjectures that the
hypertumor mechanism can lead to much longer lived tumors that are self-limiting or die out on a
longer time scale [36]. If his conjecture is correct, we should see a change in inflection in the tumor
growth. In the 1000 day time scale we used we had varied sizes of tumors, but it is important to
note that all of these tumors were continuing to grow when we ended the simulation. In particular,
we would like to see what are the eventual fates of the tumors in figures 3.6 and 3.8.
Analysis of the spatially heterogeneous steady state may provide some insight into self-
limiting tumors. With our current model this was particularly difficult since the system of ODEs
that results is implicit in the the highest-order derivative (y′′ = f(t, y, y′, y′′)). Although MATLAB
can handle such a system - in particular its ode15i solver comes to mind - the solver can only do
so for initial value problems, not boundary value problems, which we have because of the no flux
conditions at the endpoints. Thus, investigating this would require either programming our own
numerical scheme or looking at different software that can handle such problems. Additionally,
finding upper limits on the values for the numerical exploration of the basin of attraction can also
be done, though it is not immediately clear if this will give any new biological insight into tumor
growth.
Furthermore, we could modify the equation for the microvessel length density, z, to include
location dependent intratumoral pressure and a reduction VEC recruitment rate as the tumor grows.
We believe this change in the dynamics would lead to, possibly, more realistic models of spheroid
tumors.
In Chapter 3 we have shown that there is sufficient evidence that the ecological ecosystem
versus integrated tissue question can be answered by the angiogenic signaling and proliferation rates
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of each parenchymal lineages in the tumor. To find conclusive biological evidence, we would look at
relevant biological data - in particular mouse xenographs - to determine whether the same patterns
arise in vivo. Further research is warranted for investigating the effects parenchymal motility has
on tumor growth. Our work shows that varying cell motility rates can change the local density
and have a dramatic effect on the vascular network that forms. Mark Chaplain's work in modeling
vascular tumor networks suggests this as well [11]. Figures 3.6 and 3.8 hint at palisading regions
found in tumors to arise from the hypertumor mechanism. Scouring the oncological data for tumors
that have two distinct lineages separated by a region of necrosis would be a first step to resolve this
question.
In Chapter 1 we set to answer three questions. First, can the hypertumor mechanism account
for necrosis in vascularized tumors. Simulations suggest that this is a good hypothesis for biologists
to explore. In particular, the scenario depicted in Figure 3.6 shows a necrotic region appearing at
the core which is the area where necrosis occurs in spheroid tumors seen in patients [50].
Secondly, can the hypertumor mechanism account for a decrease in the size of a tumor.
The scenario pictured by Figures 3.8 and 3.9 shows a reduction in the size of the tumor after the
hypertumor forms and is established, thus the hypertumor also resolves this question affirmatively.
Lastly, can the hypertumor mechanism separate the two competing parenchymal cells into
different regions where they reside independently of the other strain, i.e., niche segregation. Figures
3.8 and 3.9 describe this separation. The region on the right of Figure 3.8 is only has the mutant
parenchymal cells while the region on the left has the original resident parenchymal cells. This is
the separation into distinct ecosystems that Nagy alluded to in [36].
The hypertumor presence, if observed in vitro or in vivo, would be a very powerful biological
force governing the dynamics of tumor cells. As an extension of this project, it would be worthwhile
to collaborate with biologists and oncologists to see if there is any evidence of hypertumors in either
animal or human studies. This could be a valuable post-doctoral position, possibly at a medical
school or interdisciplinary computational biology program.
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